Toni Andreu is the current Scientific Director of EATRIS (The European Infrastructure for Translational Medicine), a position he has held since 2018. Toni is an M.D., Ph.D. specialised in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from a clear translational perspective, from basic science to the development of cell and animal models and clinical research. During his career he has published over 180 scientific papers, numerous book chapters and supervised several PhD programs. After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute where he became Director of the Neurosciences Research Program and later CEO of the University Hospital of Bellvitge, one of the largest health care institutions in Spain.
He has also been extremely active in the field of policy-making, and has held positions as the Director of the Spanish National Institute of Health Carlos III as well as the Director General for Research and Innovation at the Catalan Ministry of Health.

Katie Ellias is the Managing Director of T1D Fund since 2018, where she has led a number of investments in companies developing T1D-oriented therapies. She currently serves as a director on the board of SAB Biotherapeutics (NASDAQ: SABS), represents the T1D Fund as a director of DiogenX, and Veralox Therapeutics, and serves on the board of Fund companies Nipuna, Therapeutics, Cour Therapeutics, Seraxis, i2O Therapeutics, and Biolinq. Ms. Ellias joined the T1D Fund from Endeavour Vision, a Geneva-based growth stage venture fund. She was previously Principal at Sofinnova Partners, Paris, a leading early-stage life sciences fund. Ms. Ellias has also held commercial and business development roles with Medtronic and started her career at McKinsey & Company. Katie holds an M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. in International Relations and Political Science from Yale University.

Molly Harper is the Chief Business Officer at Synlogic and is a member of the Board of Directors for Catalyst Pharmaceuticals and PreciseDx, bringing more than 20 years of operating experience in the biopharma industry, with a focus on translating development assets into commercialized products. She previously served as Executive Vice President of Operations for Relmada Therapeutics, and was a member of the founding team at Akcea Therapeutics, where her last position was Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper previously served in commercial leadership positions at Genzyme and Merck & Co. She holds an MBA from The Wharton School at the University of Pennsylvania, and a BA from Cornell University.

Ivo Lorenz is the Head of Biologics at Deerfield Discovery and Development in New York. A native of Switzerland, he obtained his PhD in Biochemistry from the Swiss Federal Institute of Technology. After his postdoctoral training at The Rockefeller University, Dr. Lorenz held group leader positions at the International AIDS Vaccine Initiative and at Boehringer Ingelheim Pharmaceuticals, where he gained extensive experience in biologics drug discovery and project management. He then established and led the biologics discovery team in his role as Vice President, Biologics at the Tri-Institutional Therapeutics Discovery Institute, an academic drug discovery center jointly run by Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine in New York. At Deerfield, Dr. Lorenz and his team work on a pipeline of biologics discovery and development programs to find new, innovative medicines for a variety of diseases, and advance them to the clinic.